Switch theme
Sign up to access all valuation multiples
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
1948
1.6K+
LTM Revenue $628M
LTM EBITDA $143M
$544M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kaken Pharmaceutical has a last 12-month revenue (LTM) of $628M and a last 12-month EBITDA of $143M.
In the most recent fiscal year, Kaken Pharmaceutical achieved revenue of $494M and an EBITDA of $86.2M.
Kaken Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kaken Pharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $628M | XXX | $494M | XXX | XXX | XXX |
| Gross Profit | $628M | XXX | $264M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 53% | XXX | XXX | XXX |
| EBITDA | $143M | XXX | $86.2M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 17% | XXX | XXX | XXX |
| EBIT | $125M | XXX | $65.3M | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $83.6M | XXX | $55.1M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Kaken Pharmaceutical's stock price is JPY 3844 (or $26).
Kaken Pharmaceutical has current market cap of JPY 146B (or $999M), and EV of JPY 79.3B (or $544M).
See Kaken Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $544M | $999M | XXX | XXX | XXX | XXX | $2.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Kaken Pharmaceutical has market cap of $999M and EV of $544M.
Kaken Pharmaceutical's trades at 1.1x EV/Revenue multiple, and 6.7x EV/EBITDA.
Equity research analysts estimate Kaken Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kaken Pharmaceutical has a P/E ratio of 12.0x.
See valuation multiples for Kaken Pharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $999M | XXX | $999M | XXX | XXX | XXX |
| EV (current) | $544M | XXX | $544M | XXX | XXX | XXX |
| EV/Revenue | 0.9x | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | 3.8x | XXX | 6.7x | XXX | XXX | XXX |
| EV/EBIT | 4.3x | XXX | 8.7x | XXX | XXX | XXX |
| EV/Gross Profit | 0.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 12.0x | XXX | 19.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 38.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKaken Pharmaceutical's last 12 month revenue growth is -13%
Kaken Pharmaceutical's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Kaken Pharmaceutical's rule of 40 is 3% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kaken Pharmaceutical's rule of X is -10% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Kaken Pharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -13% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | -67% | XXX | -26% | XXX | XXX | XXX |
| Rule of 40 | 3% | XXX | 3% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -10% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kaken Pharmaceutical acquired XXX companies to date.
Last acquisition by Kaken Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Kaken Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Kaken Pharmaceutical founded? | Kaken Pharmaceutical was founded in 1948. |
| Where is Kaken Pharmaceutical headquartered? | Kaken Pharmaceutical is headquartered in Japan. |
| How many employees does Kaken Pharmaceutical have? | As of today, Kaken Pharmaceutical has 1.6K+ employees. |
| Is Kaken Pharmaceutical publicy listed? | Yes, Kaken Pharmaceutical is a public company listed on TKS. |
| What is the stock symbol of Kaken Pharmaceutical? | Kaken Pharmaceutical trades under 4521 ticker. |
| When did Kaken Pharmaceutical go public? | Kaken Pharmaceutical went public in 1961. |
| Who are competitors of Kaken Pharmaceutical? | Similar companies to Kaken Pharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Kaken Pharmaceutical? | Kaken Pharmaceutical's current market cap is $999M |
| What is the current revenue of Kaken Pharmaceutical? | Kaken Pharmaceutical's last 12 months revenue is $628M. |
| What is the current revenue growth of Kaken Pharmaceutical? | Kaken Pharmaceutical revenue growth (NTM/LTM) is -13%. |
| What is the current EV/Revenue multiple of Kaken Pharmaceutical? | Current revenue multiple of Kaken Pharmaceutical is 0.9x. |
| Is Kaken Pharmaceutical profitable? | Yes, Kaken Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kaken Pharmaceutical? | Kaken Pharmaceutical's last 12 months EBITDA is $143M. |
| What is Kaken Pharmaceutical's EBITDA margin? | Kaken Pharmaceutical's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of Kaken Pharmaceutical? | Current EBITDA multiple of Kaken Pharmaceutical is 3.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
